Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AnGes has entered into a definitive agreement to obtain US marketing rights for Mitsubishi Tanabe Pharma's Collategene (DNA Plasmid with HGF gene), designed to improve ischemic condition and used as a regenerative medicine for the treatment of peripheral arterial disease.
Subscribe to our email newsletter
Under the agreement, AnGes will receive upfront payments, performance based milestone payments and payments after the product launch in accordance with its sales.
AnGes president and CEO Ei Yamada said the company is pleased to announce that the company can commence the Phase III global clinical trial of Collategene as a treatment for critical limb ischemia (CLI), an intractable disease.
"The United States takes active measures toward promoting new drug development, and the country has the largest market for the drug for CLI which cannot be treated with existing treatments," Yamada added.
"AnGes aims to obtain the marketing approval in the United States at an early date by promptly advancing the development.
"We will definitely achieve this by establishing a cooperative structure with MTPC, a strong partner we long-sought."